Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12914868 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB | |
| SCHEMBL2292164 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB | |
| SCHEMBL19532931 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB | |
| SCHEMBL16329701 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB | |
| SCHEMBL16024536 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB | |
| SCHEMBL24181348 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB | |
| SCHEMBL17144054 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB | |
| SCHEMBL4264824 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB | |
| SCHEMBL22806766 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB | |
| SCHEMBL192585 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | SINGULAR GENOMICS SYSTEMS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12215122-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240400602-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-12-05 | — | — | US | disclosed |
| US-12145960-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240316036-A1 | DISULFIDE CONTAINING THERAPEUTICS AND DIAGNOSTICS | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-09-26 | — | — | US | disclosed |
| US-20240269156-A1 | DISULFIDE CONTAINING THERAPEUTICS | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-08-15 | — | — | US | disclosed |
| US-20240174709-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-05-30 | — | — | US | disclosed |
| US-11958877-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11878993-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-01-23 | — | — | US | disclosed |
| WO-2023192586-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
| US-10738072-B1 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2020-08-11 | — | — | US | disclosed |
| WO-2020023851-A1 | BIFUNCTIONAL SUBSTITUED PYRIMIDINES AS MODULATORS OF FAK PROTEOLYSE | YALE UNIVERSITY (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2018118598-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018053354-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215122-B2 | Nucleotide analogues | NUDT1, POLN, TYMP | ALDH1A1 1629/4885TSHR 3920/4885THRB 3163/4885 |
| US-20240400602-A1 | NUCLEOTIDE ANALOGUES | ADAR, NUDT1, NSUN2 | ALDH1A1 1085/4885TSHR 2978/4885THRB 3292/4885 |
| US-20240316036-A1 | DISULFIDE CONTAINING THERAPEUTICS AND DIAGNOSTICS | GPX1, GPX4, PDIA4 | ALDH1A1 1364/4885TSHR 998/4885THRB 1639/4885 |
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | ADAR, NUDT1, NSUN2 | ALDH1A1 1085/4885TSHR 2978/4885THRB 3292/4885 |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | ALDH1A1 1313/4885TSHR 4079/4885THRB 2419/4885 |
| US-20240269156-A1 | DISULFIDE CONTAINING THERAPEUTICS | P4HB, PDIA5, PDIA4 | ALDH1A1 1621/4885TSHR 2130/4885THRB 3114/4885 |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | ALDH1A1 1313/4885TSHR 4079/4885THRB 2419/4885 |
| US-11958877-B2 | Nucleotide analogues | ITPA, POLB, NUDT1 | ALDH1A1 1313/4885TSHR 4079/4885THRB 2419/4885 |
| US-10738072-B1 | Nucleotide analogues | NUDT1, POLN, TYMP | ALDH1A1 1629/4885TSHR 3920/4885THRB 3163/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | ALDH1A1 1313/4885TSHR 4079/4885THRB 2419/4885 |
| US-20240174709-A1 | NUCLEOTIDE ANALOGUES | NUDT1, POLN, TYMP | ALDH1A1 1629/4885TSHR 3920/4885THRB 3163/4885 |
| US-11878993-B2 | Nucleotide analogues | ITPA, POLB, NUDT1 | ALDH1A1 1313/4885TSHR 4079/4885THRB 2419/4885 |
| US-12145960-B2 | Nucleotide analogues | ITPA, POLB, NUDT1 | ALDH1A1 1313/4885TSHR 4079/4885THRB 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.